On December 1, 2020, Independence announced that FutureScripts® was making a change effective January 1, 2021, to its Select Drug Program®, Value, and Premium formularies to move to a generic only albuterol HFA rescue inhaler strategy. However, due to shortages of the generic equivalent of Proair HFA, the previously announced change for Proair HFA has been postponed.
Proair typically is used in the treatment or prevention of bronchospasm in patients ages 4 and older. However, it is now being dispensed at a greater rate due to its use as a therapeutic for COVID-19 patients with respiratory issues.
When it is determined sufficient supplies of the generic equivalent (albuterol HFA aerosol) are available to satisfy prescription demands, we will move forward with the formulary tier changes. This will be announced in a future
Partners in Health UpdateSM article.
Learn more
If you have any questions about this postponement, please contact FutureScripts at 1-888-678-7012.
FutureScripts® is an independent company that provides pharmacy benefit management services. FutureScripts® is a registered trademark. All other trademarks are the property of their respective owners. ©2020 FutureScripts. All rights reserved.